

Date: September 02, 2025

To,
The Manager - Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Plot No. C/1, Block-G,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051

SYMBOL: REMUS

Sub.: Notice of the Tenth (10th) Annual General Meeting of the Company scheduled to be held on September 25, 2025

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose the Notice of the Tenth (10th) Annual General Meeting (“AGM”) of the members of the Company, which is scheduled to be held on **Thursday, September 25, 2025 at 11:30 A.M. (IST)** through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”). The Notice of the AGM forms an integral part of the Annual Report for the Financial Year 2024-25 which has been submitted to the stock exchange.

The important information related to AGM and e-voting (i.e., before & during the AGM) is as follows:

Details of AGM	Thursday, September 25, 2025, at 11:30 A.M. (IST) through Video Conference / Other Audio-Visual Means.
Cut-off date to determine the list of members entitled to receive Notice of AGM and Annual Report	Friday, August 29, 2025
Cut-off date to determine the list of members entitled for e-voting	Thursday, September 18, 2025
Cut-off date to determine list of members entitled to receive final dividend	Thursday, September 18, 2025
Remote e-voting start time and date (prior to the AGM)	From Monday, September 22, 2025, 09:00 A.M. (IST)
Remote e-voting end time and date (prior to the AGM)	Till Wednesday, September 24, 2025, 05:00 P.M. (IST)

The said Notice along with Annual Report for the Financial Year 2024-25 has been sent via email to the members of the Company whose email addresses are registered with the Registrar and Transfer Agent of the Company / Depository Participants as of the cut-off date.

The detailed procedure and instructions to cast the vote through remote e-voting or through e-voting system during the AGM and attending AGM through VC/OAVM are part of the Notice of the AGM attached herewith.

The Notice of AGM and Annual Report for the Financial Year 2024-25 are also available on the website of the Company at www.remuspharma.com.

Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.
P: 079 2999 9857

E. remus@remuspharma.com | W. www.remuspharma.com
GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536



You are requested to take the same on record.

Thanking you
For, Remus Pharmaceuticals Limited

Deval Patel

Company Secretary and Compliance Officer
ICSI Membership No.: A60090

Encl.: As Above



Remus Pharmaceuticals Limited

REGISTERED OFFICE: 1101 to 1103, South Tower, One42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS,
Ambli Bopal Road, Ahmedabad-380054, Gujarat, India.
P: 079 2999 9857

E. remus@remuspharma.com | W. www.remuspharma.com

GST NO: 24AAHCR4771P2ZQ | CIN NO: L24232GJ2015PLC084536

NOTICE OF ANNUAL GENERAL MEETING

NOTICE is hereby given that the Tenth (10th) Annual General Meeting ("AGM") of the members of **Remus Pharmaceuticals Limited** ("the Company") will be held on Thursday, September 25, 2025 at 11:30 a.m. (IST) through Video Conferencing ("VC") / Other Audio- Visual Means ("OAVM") to transact the following businesses:

ORDINARY BUSINESSSES:

1. To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31, 2025, together with the Reports of the Board of Directors and the Auditors thereon To consider and if thought fit, to pass, with or without modification(s), the following resolution as an **Ordinary Resolution:**

"RESOLVED THAT the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended on March 31, 2025, together with the Reports of the Board of Directors and Auditors thereon, as circulated to the Members, be and are hereby considered, approved and adopted."

2. To declare dividend of ₹ 0.50 (5%) per equity share of ₹ 10/- (Rupees Ten only) each for the Financial Year ended on March 31, 2025

To consider and if thought fit, to pass, with or without modification(s), the following resolution as an **Ordinary Resolution:**

"RESOLVED THAT approval of the members be and is hereby accorded to declare and pay final dividend of ₹ 0.50/- (Fifty paise only) (5%) per equity share of the face value of ₹ 10/- (Rupees Ten only) each fully paid up, of the Company, as recommended by the Board of Directors for the Financial Year ended on March 31, 2025."

3. To appoint Mr. Arpit Deepakkumar Shah (DIN: 07214641) as a director, liable to retire by rotation who has offered himself for re-appointment

To consider and, if thought fit, to pass the following resolution as an **Ordinary Resolution:**

"RESOLVED THAT in accordance with the provisions of Section 152 and other applicable provisions of the Companies Act, 2013 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), Mr. Arpit Deepakkumar Shah (DIN: 07214641), who retires by rotation as a Director at this Tenth (10th) Annual General Meeting, and being eligible, offers himself for re-appointment, be and is hereby re-appointed as a Director of the Company, who shall be liable to retire by rotation."

SPECIAL BUSINESSSES:

4. Re-appointment of Mr. Arpit Deepakkumar Shah (DIN: 07214641) as the Managing Director of the Company

To consider and if thought fit, to pass with or without modification(s), the following resolution as a **Special Resolution:**

"RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198 and 203 read with Schedule V and all other applicable provisions of the Companies Act, 2013 ("the Act") and relevant rules framed thereunder, the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") to the extent applicable, or any statutory modification(s) or re-enactment(s) thereof, the Articles of Association of the Company and pursuant to the recommendation and approval respectively of the Nomination and Remuneration Committee and the Board of Directors of the Company (the "Board"), consent of the Shareholders of the Company be and is hereby accorded to the re-appointment of Mr. Arpit Deepakkumar Shah (DIN: 07214641), as the Managing Director of the Company, to hold office for a second term of 3 (three) consecutive years commencing from January 16, 2026 to January 15, 2029 (both days inclusive), liable to retire by rotation, on such terms and conditions of appointment, including his remuneration, as set out in the Explanatory Statement annexed hereto; and

RESOLVED FURTHER THAT approval of the Company be and is hereby accorded to the Board of Directors of the Company (including any Committee thereof) to do all such acts, deeds, matters and things and to take all such steps as may be required in this connection including seeking all necessary approvals to give effect to this Resolution and to execute all necessary documents, applications, returns and writings as may be necessary, proper or expedient".

5. Re-appointment of Ms. Roma Vinodbhai Shah (DIN: 07214632) as the Whole Time Director of the Company

To consider and if thought fit, to pass with or without modification(s), the following resolution as a **Special Resolution:**

"RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198 and 203 read with Schedule V and all other applicable provisions of the Companies Act, 2013 ("the Act") and relevant rules framed thereunder, the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") to the extent applicable, or any statutory modification(s) or re-enactment(s) thereof, the Articles of Association of the Company and pursuant to the recommendation and approval respectively of the Nomination and Remuneration Committee and the Board of Directors of the Company (the "Board"), consent of the Shareholders of the Company be and is hereby accorded to the re-appointment of Ms. Roma Vinodbhai Shah (DIN: 07214632), as the Whole Time Director of the Company, to hold office for a second term of 3 (three)

consecutive years commencing from January 16, 2026 to January 15, 2029 (both days inclusive) liable to retire by rotation, on such terms and conditions of appointment, including her remuneration, as set out in the Explanatory Statement annexed hereto; and

RESOLVED FURTHER THAT approval of the Company be and is hereby accorded to the Board of Directors of the Company (including any Committee thereof) to do all such acts, deeds, matters and things and to take all such steps as may be required in this connection including seeking all necessary approvals to give effect to this Resolution and to execute all necessary documents, applications, returns and writings as may be necessary, proper or expedient”.

6. Re-appointment of Mr. Swapnil Jatinbhai Shah (DIN: 05259821) as the Chairman and Non- Executive, Non-Independent Director of the Company

To consider and if thought fit, to pass with or without modification(s), the following resolution as an **Ordinary Resolution**:

“**RESOLVED THAT** pursuant to the provisions of section 152 and other applicable provisions of the Companies Act, 2013 (“the Act”), the Companies (Appointment and Qualifications of Directors) Rules, 2014 and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 to the extent applicable, including any statutory modification(s) or amendment(s) thereto or re-enactment(s) thereof for the time being in force and pursuant to the recommendations of the Nomination and Remuneration Committee and the Board of Directors of the Company, Mr. Swapnil Jatinbhai Shah (DIN: 05259821), who was re-designated as the Chairman and Non-Executive, Non – Independent Director of the Company, with effect from May 18, 2025 and who holds office as the Chairman and Non-Executive, Non – Independent Director up to January 15, 2026 and who is eligible for being re-appointed as the Chairman and Non-Executive, Non – Independent Director, be re-appointed as the Chairman and Non-Executive, Non – Independent Director of the Company, liable to retire by rotation, to hold office for a second term of 3 (three) consecutive years commencing from January 16, 2026 to January 15, 2029 (both days inclusive); and

RESOLVED FURTHER THAT the Board of Directors of the Company (including any Committee thereof) or the Company Secretary be and are hereby authorized to do all such acts, deeds, matters and things and to take all such steps including to settle any questions, difficulties or doubts as may be necessary, proper or expedient to give effect to this resolution.”

7. Re-appointment of Mrs. Anar Swapnil Shah (DIN: 06895297) as a Non- Executive, Non- Independent Director of the Company

To consider and if thought fit, to pass with or without modification(s), the following resolution as an **Ordinary Resolution**:

“**RESOLVED THAT** pursuant to the provisions of section 152 and other applicable provisions of the Companies Act, 2013 (“the Act”), the Companies (Appointment and Qualifications of Directors) Rules, 2014 and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 to the extent applicable including any statutory modification(s) or amendment(s) thereto or re-enactment(s) thereof for the time being in force and pursuant to the recommendations of the Nomination and Remuneration Committee and the Board of Directors of the Company, Mrs. Anar Swapnil Shah (DIN: 06895297), who was re-designated as the Non-Executive, Non – Independent Director of the Company, with effect from May 18, 2025 and who holds office as the Non-Executive, Non – Independent Director up to January 15, 2026, be re-appointed as a Non-Executive, Non – Independent Director of the Company, liable to retire by rotation, to hold office for a second term of 3 (three) consecutive years commencing from January 16, 2026 to January 15, 2029 (both days inclusive); and

RESOLVED FURTHER THAT the Board of Directors of the Company (including any Committee thereof) or the Company Secretary be and are hereby authorized to do all such acts, deeds, matters and things and to take all such steps including to settle any questions, difficulties or doubts as may be necessary, proper or expedient to give effect to this resolution.”

By order of the Board of Directors
For **Remus Pharmaceuticals Limited**

Sd/-
Deval Patel
Company Secretary and Compliance Officer

Place: Ahmedabad
Date: 29/08/2025

Registered Office:
1101 to 1103, South Tower,
One 42, B/H Ashok Vatika,
Nr. Jayantilal Park BRTS,
Ambli Bopal Road,
Ahmedabad – 380 054, Gujarat
CIN: L24232GJ2015PLC084536

NOTES:

1. The Ministry of Corporate Affairs ("**MCA**") has vide its General Circular nos. 14/2020 dated April 08, 2020; 17/2020 dated April 13, 2020; 20/2020 dated May 05, 2020; and subsequent circulars issued in this regard, including latest circular no. 09/2024 dated September 19, 2024, read with the Securities and Exchange Board of India ("**SEBI**") Circular no. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020 and other relevant circulars including circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/4 dated January 05, 2023 and Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated October 03, 2024 (hereinafter collectively referred to as "**Circulars**"), and in compliance with the provisions of the Companies Act, 2013 ("**the Act**") and the SEBI (Listing Obligations and Disclosure Requirement) Regulation, 2015 ("**Listing Regulations**"), permitted the holding of the Annual General Meeting ("**AGM**") through Video Conferencing ("**VC**")/Other Audio Visual Means ("**OAVM**"), without the physical presence of the members at a common venue.
2. In compliance with the provisions of the Act read with the Circulars, the 10th AGM of the Company is being held through VC/OAVM only. Further, in accordance with the Secretarial Standard-2 ("**SS-2**") on General Meetings issued by the Institute of Company Secretaries of India ("**ICSI**") read with Guidance/Clarification dated April 15, 2020 issued by the ICSI, the proceedings of the AGM shall be deemed to be conducted at the Registered Office of the Company, which shall be the deemed venue of the AGM.
3. Explanatory Statement pursuant to the provisions of Section 102 of the Act in respect of Special Business stating material facts and reasons for the proposed resolutions and additional information as required under the Act, Regulation 36 of the Listing Regulations and Secretarial Standard-2 are annexed hereto and forms part of this notice.
4. Since this AGM is being held pursuant to the Circulars through VC/OAVM only, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxies by the Members will not be available for the AGM and hence, the Proxy Form, Attendance Slip and Route Map are not annexed to this Notice.
5. The Company has engaged the services of MUFG Intime India Private Limited (Formerly Link Intime India Private Limited) ("**MUFG**" or "**RTA**") as the agency to provide e-voting facility.
6. The Members can join the AGM through VC/OAVM mode, 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available for 1000 members on first come first served basis.
7. In line with the Circulars, the Annual Report for the Financial Year 2024-25 including Notice of the AGM, inter alia, indicating the process and manner of e-voting is being sent by e-mail, to all the Members whose e-mail ids are registered with the Company/MUFG or with the respective Depository Participant(s) for communication purposes to the Members and to all other persons so entitled and the same will also be available on the website of the Company at www.remuspharma.com and can also be accessed from the website of the Stock Exchange i.e. National Stock Exchange of India Limited ("**NSE**") at www.nseindia.com and on the website of MUFG at <https://instameet.in.mpms.mufg.com>. Additionally, in accordance with Regulation 36(1)(b) of the Listing Regulations, the Company is also sending a letter to the Members whose e-mail addresses are not registered with Company/RTA/DP providing the weblink of Company's website from where the Annual Report for Financial Year 2024-25 can be accessed.
8. Dividend as recommended by the Board of Directors, if declared at the AGM, will be paid within 30 days of declaration to those members whose names appear in the Register of Members at the close of the business hours on Thursday, September 18, 2025 in respect of shares held by them in physical form, if any, and whose names appear in the statement of beneficial ownership furnished by National Securities Depository Limited and Central Depository Services (India) Limited at the close of the business hours on Thursday, September 18, 2025 in respect of shares held by them in dematerialised form.
9. Institutional/Corporate Members (i.e. other than individuals/HUF, NRI etc.) are required to send a duly certified scanned copy (PDF/JPG Format) of its Board or governing body resolution/authorization etc., authorizing its representative to attend the AGM through VC/OAVM on its behalf and to vote through remote e-voting, pursuant to Section 113 of the Act. The said Resolution/Authorization shall through its registered e-mail address, be sent to the Scrutinizer at info@tapanshah.in with a copy marked to enotices@in.mpms.mufg.com and cs@remuspharma.com. Such Corporate Members are requested to refer '**General Guidelines for Members**' provided in this notice, for more information.
10. Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Act.
11. In case of joint holders attending the AGM, only such joint holder who is first in the order of names will be entitled to vote.
12. The SEBI has mandated the submission of the Permanent Account Number ("**PAN**") by every participant in the securities market. Members holding shares in electronic form are, therefore requested to submit their PAN to their Depository Participant(s) ("**DP**"). Members holding shares in physical form are requested to submit their PAN details to the Company's RTA.
13. Those Members who have already registered their e-mail addresses are requested to keep their e-mail

addresses validated with their DP to enable servicing of notices/documents/Reports and other communications electronically to their e-mail address in future.

14. Online Dispute Resolution Portal:
SEBI, vide Circular Nos. SEBI/HO/OIAE/OIAE_IAD-1/P/CIR/2023/131 dated 31st July, 2023, and SEBI/HO/OIAE/OIAE_IAD-1/P/CIR/2023/135 dated August 04, 2023, read with Master Circular No. SEBI/HO/OIAE/OIAE_IAD-1/P/CIR/2023/145 dated July 31, 2023 (updated as on August 11, 2023), has established a common Online Dispute Resolution Portal (“**ODR Portal**”) for resolution of disputes arising in the Indian Securities Market. Pursuant to above-mentioned circulars, post exhausting the option to resolve their grievances with the Registrar and Share Transfer Agent/the Company directly and through existing SCORES platform, the investors can initiate dispute resolution through the ODR Portal: <https://smartodr.in/login> and the same can also be accessed through the Company’s website at <https://remuspharma.com/investor-grievance/>.
15. Members who wish to obtain any information on the Company or view the Financial Statements for the Financial Year ended March 31, 2025 can send their queries at cs@remuspharma.com at least 7 (Seven) days before the date of the AGM. The same will be replied by/on behalf of the Company, suitably.
16. In compliance with the provisions of Sections 108 and other applicable provisions of the Act, read with Rule 20 of Companies (Management and Administration) Rules, 2014 and Regulation 44 of the Listing Regulations, the Company is offering only e-voting facility to all the Members of the Company, and the business will be transacted only through the electronic voting system. The Company has engaged the services of MUFG to facilitate e-voting to enable the Members to cast their votes electronically as well as for e-voting during the AGM. Resolution(s) passed by Members through e-voting are deemed to have been passed, as if they have been passed at the AGM.
17. The Register maintained under Section 170 and Section 189 of the Act will be available electronically for inspection by the Members during the AGM. Further, all the documents referred to in the Notice will also be available for electronic inspection by the Members from the date of circulation of this Notice up to the date of AGM, September 25, 2025. Members seeking to inspect such documents can send an email to cs@remuspharma.com.

Dividend

18. Pursuant to the Finance Act, 2020, dividend income is taxable in the hands of the Members and the Company is required to deduct tax at source from the dividend paid to the Members at the prescribed rates. The Members are requested to refer to the Finance Act, 2020 for the prescribed rates for various categories, and amendments thereto.

The Members are requested to update their PAN with the Company/MUFG Intime (in case of shares held in physical mode) and depositories (in case of shares held in Demat mode).

A resident individual shareholder with PAN whose income does not exceed the maximum amount not chargeable to tax or who is not liable to pay income tax, as the case may be, can submit a yearly declaration in Form No. 15G/15H, to avail the benefit of non-deduction of tax at source. The Members can submit their tax exemption forms directly to the Company at cs@remuspharma.com.

The requisite form for claiming tax exemption can be downloaded from MUFG Intime’s website. The URL for the same is as under <https://web.in.mpms.mufg.com/client-downloads.html>. On this page, select the General tab. All the forms are available under the head “Form 15G/15H/10F”. The aforementioned forms (duly completed and signed) are required to be sent to the Company.

Incomplete and/or unsigned forms and declarations will not be considered by the Company. The Members may note that in case the tax on said interim/final dividend is deducted at a higher rate in absence of receipt of the aforementioned details/documents, the option is available to the Members to file the return of income as per the Income Tax Act, 1961 and claim an appropriate refund, if eligible.

Non-resident Members can avail beneficial rates under a tax treaty between India and their country of residence, subject to providing necessary documents i.e. No Permanent Establishment and Beneficial Ownership Declaration, Tax Residency Certificate, Form 10F, any other document which may be required to avail the tax treaty benefits. Please note that the Members who have PAN may not be eligible for Double Taxation Avoidance Agreement (‘DTAA’) benefits if the e-filed Form 10F is not furnished.

Members who wish to claim dividends, that remained unclaimed, are requested to correspond with the Company at cs@remuspharma.com. Members are requested to note that dividends not encashed or claimed within 7 (seven) years from the date of transfer to the Company’s Unpaid Dividend Account, will be transferred to the Investor Education and Protection Fund (‘IEPF’) maintained by the Government of India. Further, if the dividend amount remains unpaid for 7 (seven) consecutive years, then the corresponding shares will also be transferred to IEPF.

GENERAL GUIDELINES FOR MEMBERS

1. The voting rights of shareholders shall be in proportion to their share of the paid-up equity share capital of the Company as on the cut-off date i.e. Thursday, September 18, 2025. A person whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the cut-off date only shall be entitled to avail the facility of remote e-voting, as well as voting at the AGM. A person who is not a Member as on the cut-off date, should treat this Notice for information purposes only.

2. The remote e-voting period shall commence on Monday, September 22, 2025 at 09:00 A.M. (IST) and ends on Wednesday, September 24, 2025 at 05:00 P.M. (IST). Once the vote on a resolution is casted by the Member, the Member shall not be allowed to change it subsequently.
3. Members are provided with the facility for voting through e-voting system during the VC/OAVM proceedings at the AGM and Members participating at the AGM, who have not already casted their vote by remote e-voting, are eligible to exercise their right to vote at the AGM.
4. Members who have already casted their vote by remote e-voting prior to the AGM will be eligible to participate at the AGM but shall not be entitled to cast their vote again on such resolution(s) for which the Member has already casted their vote through remote e-voting.
5. The Chairman shall, at the AGM, at the end of discussion on the resolutions on which voting is to be held, allow voting, by use of remote e-voting system for all those Members who are present during the AGM through VC/OAVM but have not cast their votes by availing the remote e-voting facility. The remote e-voting module shall be disabled by MUFG for voting 15 minutes after the conclusion of the Meeting.
6. The Board has appointed Mr. Tapan Shah, Practicing Company Secretary (Membership No.: F4476 & COP No.: 2839) (the “**Scrutinizer**”) as a scrutinizer to scrutinize the voting and remote e-voting process in a fair and transparent manner.
7. As per the provisions of Section 72 of the Act, facility for making nomination is available for the Members in respect of shares held by them. Members holding shares in electronic mode may contact their respective Depository Participant for availing this facility.
8. In case a person has become a Member of the Company after sending of the Notice but on or before the cut-off date, he/she may obtain the User ID by writing an email to enotices@in.mpms.mufg.com or by contacting on: - Tel.: 022 - 4918 6000.
9. The Scrutinizer shall submit his consolidated report to the Chairman within two working days from the conclusion of the AGM. The results declared along with the Scrutinizer’s Report shall be communicated to NSE, where the shares of the Company are listed and shall be placed on the Company’s website of the Company at www.remuspharma.com and on the website of share transfer agent, MUFG at <https://instavote.linkintime.co.in> immediately after the result is declared by the Chairman or any other person authorised by the Chairman.
10. In case the email address is not registered with the Company/Depository Participant/RTA, please follow the process of registering the same as mentioned below:

Physical Holding	Send a request to RTA, MUFG Intime India Private Limited at https://web.in.mpms.mufg.com/helpdesk/Service_Request.html giving details of Folio number, Name of the shareholder, scanned copy of the share certificate (Front and Back), PAN (Self attested scanned copy of PAN Card), AADHAR (Self attested scanned copy of Aadhar Card) for registering email address. Please send your bank detail with original cancelled cheque to our RTA at C-101, 247 Park, L.B.S Marg, Vikhroli (W), Mumbai-400083 along with letter mentioning folio no. if not registered already.
Demat Holding	Please contact your Depository Participant (DP) to register/ update your email address and bank account details.
11. Members who have not registered their e-mail address so far are requested to register their e-mail for receiving all communications including Annual Report, Notices and Circulars etc. from the Company electronically.
12. Members must quote their Folio No./Demat Account No. and contact details such as e-mail address, contact no. etc. in all their correspondence with the Company and its Registrar and Share Transfer Agent, MUFG.
13. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. To prevent fraudulent transactions, Members are advised to exercise due diligence and notify the Company, or their DP as the case may be, of any change in address or demise of any Member in a timely manner. Members are also advised not to leave their demat account(s) dormant for long. Periodic statement of holding should be obtained from concerned DP and holdings should be verified, from time to time.

INSTRUCTIONS FOR E-VOTING AND JOINING THE AGM

In terms of SEBI circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants.

Shareholders are advised to update their mobile number and email Id correctly in their demat accounts to access remote e-Voting facility.

A. LOGIN METHOD FOR INDIVIDUAL SHAREHOLDERS HOLDING SECURITIES IN DEMAT MODE:

a. Individual Shareholders holding securities in demat mode with NSDL

METHOD 1 - NSDL IDeAS facility

Shareholders registered for IDeAS facility:

- a) Visit URL: <https://eservices.nsdl.com> and click on “Beneficial Owner” icon under “IDeAS Login Section”.

- b) Click on "Beneficial Owner" icon under "IDeAS Login Section".
- c) Post successful authentication, you will be able to see e-Voting services under Value added services section. Click on "Access to e-Voting" under e-Voting services.
- d) Click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.



Shareholders not registered for IDeAS facility:

- a) To register, visit URL: <https://eservices.nsdl.com> and select "Register Online for IDeAS Portal" or click on <https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp>
- b) Enter 8-character DP ID, 8-digit Client ID, Mobile no, Verification code & click on "Submit".
- c) Enter the last 4 digits of your bank account / generate 'OTP'
- d) Post successful registration, user will be provided with Login ID and password. Follow steps given above in points (a-d).

METHOD 2 - NSDL e-voting website

- a) Visit URL: <https://www.evoting.nsdl.com>
- b) Click on the "Login" tab available under 'Shareholder/Member' section.
- c) Enter User ID (i.e., your 16-digit demat account no. held with NSDL), Password/OTP and a Verification Code as shown on the screen.
- d) Post successful authentication, you will be redirected to NSDL depository website wherein you will be able to see e-Voting services under Value added services. Click on "Access to e-Voting" under e-Voting services.
- e) Click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

METHOD 3 - NSDL OTP based login

- a) Visit URL: <https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp>
- b) Enter your 8 - character DP ID, 8 - digit Client Id, PAN, Verification code and generate OTP.
- c) Enter the OTP received on your registered email ID/ mobile number and click on login.
- d) Post successful authentication, you will be redirected to NSDL depository website wherein you

will be able to see e-Voting services under Value added services. Click on "Access to e-Voting" under e-Voting services.

- e) Click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

b. Individual Shareholders registered with CDSL Easi/ Easiest facility

METHOD 1 - CDSL Easi/ Easiest facility:

Shareholders registered for Easi/ Easiest facility:

- a) Visit URL: <https://web.cdslindia.com/myeasitoken/Home/Login> or www.cdslindia.com & click on New System Myeasi Tab.
- b) Enter existing username, Password & click on "Login".
- c) Post successful authentication, user will be able to see e-voting option. The evoting option will have links of e-voting service providers i.e., MUFG InTime. Click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

Shareholders not registered for Easi/ Easiest facility:

- a) To register, visit URL: <https://web.cdslindia.com/myeasitoken/Registration/EasiRegistration> / <https://web.cdslindia.com/myeasitoken/Registration/EasiestRegistration>
- b) Proceed with updating the required fields for registration.
- c) Post successful registration, user will be provided username and password. Follow steps given above in points (a-c).

METHOD 2 - CDSL e-voting page

- a) Visit URL: <https://www.cdslindia.com>
- b) Go to e-voting tab.
- c) Enter 16-digit Demat Account Number (BO ID) and PAN No. and click on "Submit".
- d) System will authenticate the user by sending OTP on registered Mobile and Email as recorded in Demat Account
- e) Post successful authentication, user will be able to see e-voting option. The evoting option will have links of e-voting service providers i.e., MUFG InTime. Click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

c. Individual Shareholders holding securities in

demat mode with Depository Participant

Individual shareholders can also login using the login credentials of your demat account through your depository participant registered with NSDL / CDSL for e-voting facility.

- Login to DP website
- After Successful login, user shall navigate through "e-voting" option.
- Click on e-voting option, user will be redirected to NSDL / CDSL Depository website after successful authentication, wherein user can see e-voting feature.
- Post successful authentication, click on "MUFG InTime" or "e-voting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

B. LOGIN METHOD FOR SHAREHOLDERS HOLDING SECURITIES IN PHYSICAL MODE/NON-INDIVIDUAL SHAREHOLDERS HOLDING SECURITIES IN DEMAT MODE.

Shareholders holding shares in physical mode / Non-Individual Shareholders holding securities in demat mode as on the cut-off date for e-voting may register and vote on InstaVote as under:

STEP 1: LOGIN / SIGNUP to InstaVote

Shareholders registered for INSTAVOTE facility:

- Visit URL: <https://instavote.linkintime.co.in> & click on "Login" under 'SHARE HOLDER' tab.
- Enter details as under:
 - User ID: Enter User ID
 - Password: Enter existing Password
 - Enter Image Verification (CAPTCHA) Code
 - Click "Submit".

(Home page of e-voting will open. Follow the process

InstaVote USER ID	NSDL	User ID is 8 Character DP ID followed by 8 Digit Client ID (e.g.IN123456) and 8 digit Client ID (eg.12345678).
	CDSL	User ID is 16 Digit Beneficiary ID.
	Shares held in physical form	User ID is Event No + Folio no, registered with the Company

given under "Steps to cast vote for Resolutions")

Shareholders not registered for INSTAVOTE facility:

Visit URL: <https://instavote.linkintime.co.in> & click on "Sign Up" under 'SHARE HOLDER' tab & register with details as under:

- User ID: Enter User ID
- PAN: Enter your 10-digit Permanent Account Number (PAN) (Shareholders who have not updated their PAN with the Depository Participant (DP)/ Company

shall use the sequence number provided to you, if applicable.

- DOB/DOI: Enter the Date of Birth (DOB) / Date of Incorporation (DOI) (As recorded with your DP/ Company - in DD/MM/YYYY format)
- Bank Account Number: Enter your Bank Account Number (last four digits), as recorded with your DP/Company.
 - Shareholders holding shares in NSDL form, shall provide 'D' above
 - Shareholders holding shares in physical form but have not recorded 'C' and 'D', shall provide their Folio number in 'D' above
- Set the password of your choice.
(The password should contain minimum 8 characters, at least one special Character (!#\$%&*), at least one numeral, at least one alphabet and at least one capital letter).
- Enter Image Verification (CAPTCHA) Code.
- Click "Submit" (You have now registered on InstaVote).

InstaVote USER ID	NSDL	User ID is 8 Character DP ID followed by 8 Digit Client ID (e.g.IN123456) and 8 digit Client ID (eg.12345678).
	CDSL	User ID is 16 Digit Beneficiary ID.
	Shares held in physical form	User ID is Event No + Folio no, registered with the Company

Post successful registration, click on "Login" under 'SHARE HOLDER' tab & follow steps given above in points (a-b).

STEP 2: STEPS TO CAST VOTE FOR RESOLUTIONS THROUGH INSTAVOTE

- Post successful authentication and redirection to InstaVote inbox page, you will be able to see the "Notification for e-voting".
- Select 'View' icon. E-voting page will appear.
- Refer the Resolution description and cast your vote by selecting your desired option 'Favour / Against' (If you wish to view the entire Resolution details, click on the 'View Resolution' file link).
- After selecting the desired option i.e. Favour / Against, click on 'Submit'.
- A confirmation box will be displayed. If you wish to confirm your vote, click on 'Yes', else to change your vote, click on 'No' and accordingly modify your vote.

NOTE: Shareholders may click on "Vote as per Proxy Advisor's Recommendation" option and view proxy advisor recommendations for each resolution before casting vote. "Vote as per Proxy Advisor's Recommendation" option provides access to expert insights during the e-Voting process. Shareholders may modify their vote before final submission.

Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently.

C. GUIDELINES FOR INSTITUTIONAL SHAREHOLDERS ("CUSTODIAN / CORPORATE BODY/ MUTUAL FUND")

STEP 1 – Custodian / Corporate Body/ Mutual Fund Registration

- Visit URL: <https://instavote.linkintime.co.in>
- Click on "Sign Up" under "Custodian / Corporate Body/ Mutual Fund"
- Fill up your entity details and submit the form.
- A declaration form and organization ID is generated and sent to the Primary contact person email ID (which is filled at the time of sign up). The said form is to be signed by the Authorised Signatory, Director, Company Secretary of the entity & stamped and sent to insta.vote@linkintime.co.in.
- Thereafter, Login credentials (User ID; Organisation ID; Password) is sent to Primary contact person's email ID. (You have now registered on InstaVote)

STEP 2 – Investor Mapping

- Visit URL: <https://instavote.linkintime.co.in> and login with InstaVote Login credentials.
- Click on "Investor Mapping" tab under the Menu Section
- Map the Investor with the following details:
 - 'Investor ID' – Investor ID for NSDL demat account is 8 Character DP ID followed by 8 Digit Client ID i.e., IN00000012345678; Investor ID for CDSL demat account is 16 Digit Beneficiary ID.
 - 'Investor's Name' - Enter Investor's Name as updated with DP.
 - 'Investor PAN' - Enter your 10-digit PAN.
 - 'Power of Attorney' - Attach Board resolution or Power of Attorney.
NOTE: File Name for the Board resolution/ Power of Attorney shall be – DP ID and Client ID or 16 Digit Beneficiary ID. Further, Custodians and Mutual Funds shall also upload specimen signatures.
- Click on Submit button. (The investor is now mapped with the Custodian / Corporate Body/ Mutual Fund Entity). The same can be viewed under the "Report Section".

HELPDESK:

Individual Shareholders holding securities in demat mode:

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at: 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no.: 1800 22 55 33

STEP 3 – Steps to cast vote for Resolutions through InstaVote

The corporate shareholder can vote by two methods, during the remote e-voting period.

METHOD 1 - VOTES ENTRY

- Visit URL: <https://instavote.linkintime.co.in> and login with InstaVote Login credentials.
- Click on "Votes Entry" tab under the Menu section.
- Enter the "Event No." for which you want to cast vote. Event No. can be viewed on the home page of InstaVote under "On-going Events".
- Enter "16-digit Demat Account No."
- Refer the Resolution description and cast your vote by selecting your desired option 'Favour / Against' (If you wish to view the entire Resolution details, click on the 'View Resolution' file link). After selecting the desired option i.e. Favour / Against, click on 'Submit'.
- A confirmation box will be displayed. If you wish to confirm your vote, click on 'Yes', else to change your vote, click on 'No' and accordingly modify your vote.

(Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently).

METHOD 2 - VOTES UPLOAD

- Visit URL: <https://instavote.linkintime.co.in> and login with InstaVote Login credentials.
- After successful login, you will see "Notification for e-voting".
- Select "View" icon for "Company's Name / Event number".
- E-voting page will appear.
- Download sample vote file from "Download Sample Vote File" tab.
- Cast your vote by selecting your desired option 'Favour / Against' in the sample vote file and upload the same under "Upload Vote File" option.
- Click on 'Submit'. 'Data uploaded successfully' message will be displayed.

(Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently).

Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode:

Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode facing any technical issue in login may contact INSTAVOTE helpdesk by sending a request at enotices@in.mpms.mufig.com or contact on:- Tel: 022 – 4918 6000.

Forgot Password:

Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode:

Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode have forgotten the USER ID [Login ID] or Password or both then the shareholder can use the “Forgot Password” option available on: <https://instavote.linkintime.co.in>.

- Click on “Login” under ‘SHARE HOLDER’ tab.
- Click “forgot password?”
- Enter User ID, select Mode and Enter Image Verification code (CAPTCHA).
- Click on “SUBMIT”

In case Custodian / Corporate Body/ Mutual Fund has forgotten the USER ID [Login ID] or Password or both then the shareholder can use the “Forgot Password” option available on: <https://instavote.linkintime.co.in>

- Click on ‘Login’ under “Custodian / Corporate Body/ Mutual Fund” tab
- Click “forgot password?”
- Enter User ID, Organization ID and Enter Image Verification code (CAPTCHA).
- Click on “SUBMIT”

In case shareholders have a valid email address, Password will be sent to his / her registered e-mail address. Shareholders can set the password of his/her choice by providing information about the particulars of the Security Question and Answer, PAN, DOB/DOI etc. The password should contain a minimum of 8 characters, at least one special character (!#\$%&*), at least one numeral, at least one alphabet and at least one capital letter.

Individual Shareholders holding securities in demat mode with NSDL/ CDSL has forgotten the password:

Individual Shareholders holding securities in demat mode have forgotten the USER ID [Login ID] or Password or both, then the Shareholders are advised to use Forget User ID and Forget Password option available at above mentioned depository/ depository participants website.

General Instructions - Shareholders

- It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

- For shareholders/ members holding shares in physical form, the details can be used only for voting on the resolutions contained in this Notice.
- During the voting period, shareholders/ members can login any number of time till they have voted on the resolution(s) for a particular “Event”.

INSTAMEET VC INSTRUCTIONS FOR SHAREHOLDERS

In terms of Ministry of Corporate Affairs (MCA) General Circular No. 09/2024 dated 19.09.2024, the Companies can conduct their AGMs/ EGMs on or before 30 September 2025 by means of Video Conference (VC) or other audio-visual means (OAVM).

Shareholders are advised to update their mobile number and email Id correctly in their demat accounts to access InstaMeet facility.

Login method for shareholders to attend the General Meeting through InstaMeet:

- a) Visit URL: <https://instameet.in.mpms.mufig.com> & click on “Login”.
- b) Select the “Company Name” and register with your following details:
- c) Select Check Box:
 - **Demat Account No.:** Shareholders holding shares in NSDL/ CDSL demat account shall select check box - Demat Account No. and enter the 16-digit demat account number.
 - **Folio No.:** Shareholders holding shares in physical form shall select check box – Folio No. and enter the Folio Number registered with the company.
 - **PAN:** Shareholders shall select check box – PAN and enter 10-digit Permanent Account Number (PAN). Shareholders who have not updated their PAN with the Depository Participant (DP)/ Company shall use the sequence number provided by MUFG Intime, if applicable.
 - **Mobile No.:** Mobile No. as updated with DP is displayed automatically. Shareholders who have not updated their Mobile No with the DP shall enter the mobile no.
 - **Email ID:** Email Id as updated with DP is displayed automatically. Shareholders who have not updated their Mobile No with the DP shall enter the mobile no.
- d) Click “Go to Meeting”, you are now registered for InstaMeet, and your attendance is marked for the meeting.

Instructions for shareholders to Speak during the General Meeting through InstaMeet:

- a) Shareholders who would like to speak during the meeting must register their request with the company by sending request at cs@remuspharma.com.
- b) Shareholders will get confirmation on first cum first served basis depending upon the provision made by the company.
- c) Shareholders will receive “speaking serial number” once they mark attendance for the meeting. Please remember speaking serial number and start your conversation

with panellist by switching on video mode and audio of your device.

- d) Other shareholder who has not registered as “Speaker Shareholder” may still ask questions to the panellist via active chat-board during the meeting.

**Shareholders are requested to speak only when moderator of the meeting/ management announce the name and serial number for speaking.*

Instructions for Shareholders to Vote during the General Meeting through InstaMeet:

Once the electronic voting is activated during the meeting, shareholders who have not exercised their vote through the remote e-voting can cast the vote as under:

- a) On the Shareholders VC page, click on the link for e-Voting “Cast your vote”
- b) Enter your 16-digit Demat Account No. / Folio No. and OTP (received on the registered mobile number/ registered email Id) received during registration for InstaMEET
- c) Click on ‘Submit’.
- d) After successful login, you will see “Resolution Description” and against the same the option “Favour/ Against” for voting.
- e) Cast your vote by selecting appropriate option i.e. “Favour/ Against” as desired. Enter the number of shares (which represents no. of votes) as on the cut-off date under ‘Favour/Against’.
- f) After selecting the appropriate option i.e. Favour/Against as desired and you have decided to vote, click on “Save”. A confirmation box will be displayed. If you wish to confirm your vote, click on “Confirm”, else to change your vote, click on “Back” and accordingly modify your vote. Once you confirm your vote on the resolution, you will not be allowed to modify or change your vote subsequently.

Note:

- a) Shareholders/ Members, who will be present in the AGM through Insta Meet facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting facility during the meeting.
- b) Shareholders/ Members who have voted through Remote e-Voting prior to the General Meeting will be eligible to attend/ participate in the General Meeting through Insta Meet. However, they will not be eligible to vote again during the meeting.
- c) Shareholders/ Members are encouraged to join the Meeting through Tablets/ Laptops connected through broadband for better experience.
- d) Shareholders/ Members are required to use Internet with a good speed (preferably 2 MBPS download stream) to avoid any disturbance during the meeting.
- e) Please note that Shareholders/ Members connecting from Mobile Devices or Tablets or through Laptops connecting via Mobile Hotspot may experience Audio/Visual loss due

to fluctuation in their network. It is therefore recommended to use stable Wi-Fi or LAN connection to mitigate any kind of aforesaid glitches.

Helpdesk:

Shareholders facing any technical issue in login may contact INSTAMEET helpdesk by sending a request at instameet@in.mpms.mufig.com or contact on:- Tel: 022 – 4918 6000 / 4918 6175.

GENERAL SHAREHOLDER INFORMATION:

Speaker Registration:

1. Members who would like to express their views / ask questions during the AGM may register themselves as a speaker by sending their request, mentioning their name, demat account number / folio number, e-mail id and mobile number along with their views / questions / queries, if any, at cs@remuspharma.com at least 3 days before the date of AGM i.e. on or before Monday, September 22, 2025, 5:00 P.M. (IST).
2. Only registered speakers will be allowed to express their views / ask questions during the AGM for a maximum time allotted, once the floor is open for Members’ queries. The Company reserves the right to restrict the number of speakers to only those Members who have registered themselves and number of questions depending on the availability of time during the meeting.
3. The shareholders who do not wish to speak during the AGM but have queries may send their queries, mentioning their name, demat account number / folio number, e-mail id and mobile number, to cs@remuspharma.com. Such queries will be suitably replied to by the Company via e-mail.

STATEMENT / EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013 AND ADDITIONAL INFORMATION AS REQUIRED UNDER SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 AND CIRCULARS ISSUED THEREUNDER

Item No. 4

Mr. Arpit Deepakkumar Shah (DIN: 07214641) was re-designated as Managing Director of the Company by the members in the Extra-ordinary General Meeting held on January 21, 2023, for a term of 3 (three) years with effect from January 16, 2023 and had also approved his remuneration. Subsequently, his remuneration was revised and approved by the shareholders in the Ninth (09th) Annual General Meeting held on September 20, 2024. As per the terms of his appointment, the current tenure of Mr. Arpit Deepakkumar Shah, as the Managing Director is due for completion on January 15, 2026.

Hence, on the recommendations of Nomination & Remuneration Committee (NRC), the Board of Directors in its meeting held on August 29, 2025, have approved the re-appointment of Mr. Arpit Deepakkumar Shah as the Managing Director of the Company with effect from January 16, 2026, to hold office for a second term of 3 (three) consecutive years commencing from January 16, 2026 to January 15, 2029 (both days inclusive) liable to retire by rotation, at the same remuneration as he was receiving before

re-appointment, subject to approval by the members of the Company in this AGM.

Mr. Arpit Deepakkumar Shah is the Promoter and serves as the Managing Director of the Company. An engineer by qualification, he brings over 15 years of experience in business development and strategic planning. He plays a pivotal role in driving the Company's growth and expansion, leading business development and marketing initiatives with a strong focus on identifying new geographies, building international partnerships, and expanding the company's footprint across semi-regulated and emerging markets. His leadership has been instrumental in strengthening Remus's global presence and fostering sustainable growth.

Particulars of his qualification, brief resume, area of expertise and other details are provided in the Annexure - A attached to this Notice.

The statement pursuant to Section II of Part II of Schedule V of the Companies Act, 2013 is annexed hereto as Annexure - B.

Mr. Arpit Deepakkumar Shah is entitled to the following remuneration:

- (a) Salary :** ₹ 2,29,20,000/- p.a. (₹ 19,10,000 p.m.)
- (b) Perquisites :** In addition to salary, the following perquisites shall be allowed to the Managing Director

CATEGORY - "A"

- i) Medical Allowance for incurring expenses for self and family: ₹ 180,000 p.a. (₹ 15,000 p.m.)
- ii) Leave Travel Allowance for leave travel fare for the Managing Director and his family once in a year: ₹ 180,000 p.a. (₹ 15,000 p.m.)
- iii) Attire Allowance: ₹ 120,000 p.a. (₹ 10,000 p.m.)

CATEGORY - "B"

- i) The Company shall contribute towards Provident Fund/ Superannuation Fund/Annuity Fund provided that such contributions either singly or put together shall not exceed the tax-free limit prescribed under the Income-tax Act, if opted by the Managing Director.
- ii) The Company shall pay Gratuity and other retirement benefits as per statutory laws applicable to the Company.
- iii) The Company shall pay Leave encashment to the Managing director, as per policy of the Company. However, the leave accumulated but not availed of will be allowed to be encashed as per policy of the Company.
- iv) The Company shall deduct and deposit the Income Tax (TDS) on monthly basis as per applicable Income Tax laws.

The perquisite under this Category shall not be included in the computation of ceiling on remuneration.

CATEGORY - "C"

1. The Company shall provide a Car at the entire cost of the Company for use for the business of the Company. The driver cost, fuel cost, and maintenance cost, if any for the same shall be borne by Company and ₹ 2,500 per month towards use of car for personal purposes shall be recovered by the Company.

2. The Company shall provide reimbursement of telephone including mobile phone and Internet connection at the residence of the Managing Director on provision of bills to the company.
3. The Managing Director shall not be entitled to sitting fees for attending meetings of the Board of Directors or Committees thereof. He shall, however, be reimbursed the actual travelling, lodging and boarding expenses incurred by him for attending meetings of the Board of Directors and/or committees thereof.
4. In the event of cessation of office during any financial year, a ratable proportion of the aforesaid remuneration shall be payable by the Company.
5. The Managing Director shall be entitled to reimbursement of all expenses incurred in connection with the business of the Company.
6. "Family" means the spouse, dependent children and dependent parents of Managing Director.

In accordance with the applicable provisions of the Companies Act, 2013, approval of members is being sought, by way of special resolution, for re-appointment of Mr. Arpit Deepakkumar Shah as the Managing Director of the Company.

The Company has received a Notice in writing from a member of the Company under Section 160 of the Companies Act, 2013 proposing his candidature as a Director on the Board of the Company.

With regard to the proposed appointment, the Company has received consent from Mr. Arpit Deepakkumar Shah to act as a Managing Director, a declaration that he is not disqualified from being appointed as a Director in terms of Section 164 of the Act and a declaration to the effect that she is not debarred or disqualified from being appointed or continuing as a director of any company by the SEBI or Ministry of Corporate Affairs or any such authority.

Accordingly, the Board recommends the resolution set forth in Item No. 4 relating to re-appointment of Mr. Arpit Deepakkumar Shah as the Managing Director of the Company, by way of Special Resolution.

Except Mr. Arpit Deepakkumar Shah and Ms. Roma Vinodbhai Shah (spouse of Mr. Arpit Deepakkumar Shah), no other director(s) and Key Managerial Personnel(s) or their relatives, is in any way, concerned or interested, financially or otherwise, in this resolution.

Item No. 5

Ms. Roma Vinodbhai Shah (DIN: 07214632) was re-designated as the Whole -Time Director of the Company by the members in the Extra-ordinary General Meeting held on January 21, 2023, for a term of 3 (three) years with effect from January 16, 2023 and had also approved her remuneration. Subsequently, her remuneration was revised and approved by the shareholders in the Ninth (09th) Annual General Meeting held on September 20, 2024. As per the terms of her appointment, the current tenure of Ms. Roma Vinodbhai Shah, as the Whole -Time Director is due for completion on January 15, 2026.

Hence, on the recommendations of Nomination & Remuneration Committee (NRC), the Board of Directors in its meeting held on August 29, 2025, have approved the re-appointment of Mrs. Roma Vinodbhai Shah as the Whole -Time Director of the Company with effect from January 16, 2026, to hold office for a second term of 3 (three) consecutive years commencing from January 16, 2026 to January 15, 2029 (both days inclusive) liable to retire by rotation, at the same remuneration as she was receiving before re-appointment, subject to approval by the members of the Company in this AGM.

Ms. Roma Vinodbhai Shah, the Promoter and Whole Time Director of the Company holds a master's degree in Pharmaceutical Manufacturing from the USA and a bachelor's degree in Pharmacy from India. She brings deep technical expertise and global perspective to the organization. She has been a strong pillar in driving the Company's success across Regulatory Affairs, R&D, and strategic business management. Her specialization in critical technical areas ensures the Company's adherence to international quality standards and regulatory compliance, with deep industry insights, ensuring regulatory excellence and global market readiness.

Particulars of her qualification, brief resume, area of expertise and other details are provided in the Annexure – A attached to this Notice.

The statement pursuant to Section II of Part II of Schedule V of the Companies Act, 2013 is annexed hereto as Annexure – B.

Ms. Roma Vinodbhai Shah is entitled to the following remuneration:

- (a) Salary:** ₹ 1,20,00,000/- p.a. (₹ 10,00,000 p.m.)
- (b) Perquisites:** In addition to salary, the following perquisites shall be allowed to the Director

CATEGORY - "A"

- i) Medical Allowance for incurring expenses for self and family: ₹ 180,000 p.a. (₹ 15,000 p.m.)
- ii) Leave Travel Allowance for leave travel fare for the Director and his family once in a year: ₹ 120,000 p.a (₹ 10,000 p.m.)
- iii) Attire Allowance: ₹ 120,000 p.a (₹ 10,000 p.m.)

CATEGORY - "B"

- i) The Company shall contribute towards Provident Fund/ Superannuation Fund/Annuity Fund provided that such contributions either singly or put together shall not exceed the tax-free limit prescribed under the Income-tax Act, if opted by the director.
- ii) The Company shall pay Gratuity and other retirement benefits as per statutory laws applicable to the Company.
- iii) The Company shall pay Leave encashment to director, as per rules of the Company. However, the leave accumulated but not availed of will be allowed to be encashed as per rules of the Company.
- iv) The Company shall deduct and deposit the Income Tax (TDS) on monthly basis as per applicable Income Tax laws.

The perquisite under this Category shall not be included in the computation of ceiling on remuneration.

CATEGORY - "C"

1. The Company shall provide a Car at the entire cost of the Company for use for the business of the Company. The driver cost, Fuel cost and maintenance cost, if any for the same shall be borne by Company and ₹ 3,000 per month towards use of car for personal purposes shall be recovered by the Company.
2. The Company shall provide telephone including mobile phone and Internet connection at the residence of the Director on provision of bills to the company.
3. The Director shall not be entitled to sitting fees for attending meetings of the Board of Directors or Committees thereof. He shall, however, be reimbursed the actual travelling, lodging and boarding expenses incurred by him for attending meetings of the Board of Directors and/or committees thereof.
4. In the event of cessation of office during any financial year, a ratable proportion of the aforesaid remuneration shall be payable by the Company.
5. The Director shall be entitled to reimbursement of all expenses incurred in connection with the business of the Company.
6. "Family" means the spouse, dependent children and dependent parents of Director.

In accordance with the applicable provisions of the Companies Act, 2013, approval of members is being sought, by way of a special resolution, for re-appointment of Ms. Roma Vinodbhai Shah (DIN: 07214632) as the Whole Time Director of the Company.

The Company has received a Notice in writing from a member of the Company under Section 160 of the Companies Act, 2013 proposing her candidature as Director on the Board of the Company.

With regard to the proposed appointment, the Company has received consent from Ms. Roma Vinodbhai Shah to act as a Whole Time Director, a declaration that she is not disqualified from being appointed as Director in terms of Section 164 of the Act and a declaration to the effect that she is not debarred or disqualified from being appointed or continuing as a director of any company by the SEBI or Ministry of Corporate Affairs or any such authority.

Accordingly, the Board recommends the resolution set forth in Item No. 5 relating to re-appointment of Ms. Roma Vinodbhai Shah (DIN: 07214632) as the Whole Time Director of the Company, by way of a Special Resolution.

Except Ms. Roma Vinodbhai Shah and Mr. Arpit Deepakkumar Shah (spouse of Ms. Roma Vinodbhai Shah), no other director(s) and Key Managerial Personnel(s) or their relatives, is in any way, concerned or interested, financially or otherwise, in this resolution.

Item No. 6

Mr. Swapnil Jatinbhai Shah (DIN: 05259821) was re-designated as Chairman and Whole Time Director of the Company by the members in the Extra-ordinary General Meeting held on January

21, 2023, for a term of 3 (three) years with effect from January 16, 2023 and had also approved his remuneration. Subsequently, upon his request, the Nomination and Remuneration Committee ("NRC") and the Board of Directors at their respective meetings held on May 17, 2025, re-designated him as the Chairman and Non- Executive, Non- Independent Director of the Company with effect from May 18, 2025 for remaining period of his tenure. As per the terms of his appointment, the current tenure of Mr. Swapnil Jatinbhai Shah, as the Chairman and Non- Executive, Non- Independent Director is due for completion on January 15, 2026.

Hence, on the recommendations of Nomination & Remuneration Committee (NRC), the Board of Directors in its meeting held on August 29, 2025, have approved the re-appointment of Mr. Swapnil Jatinbhai Shah as the Chairman and Non- Executive, Non- Independent Director of the Company with effect from January 16, 2026, to hold office for a second term of 3 (three) consecutive years commencing from January 16, 2026 to January 15, 2029 (both days inclusive) liable to retire by rotation.

The Company has received a Notice in writing from a member of the Company under Section 160 of the Companies Act, 2013 proposing his candidature as Director on the Board of the Company.

With regard to the proposed appointment, the Company has received consent from Mr. Swapnil Jatinbhai Shah to act as a Director, a declaration that he is not disqualified from being appointed as Director in terms of Section 164 of the Act and a declaration to the effect that he is not debarred or disqualified from being appointed or continuing as a director of any company by the SEBI or Ministry of Corporate Affairs or any such authority.

Mr. Swapnil Shah holds a master's degree in Business Administration with a specialization in Finance & International Business from Hofstra University, New York, and a bachelor's degree in Chemical Engineering from Nirma University.

Mr. Swapnil Shah is the Promoter and Chairman and Non- Executive Director and a key strategic advisor to the Company. With over 18 years of experience in the pharmaceutical sector, he brings valuable insights in business development, corporate strategy, and global operations. While not involved in day-to-day operations, he continues to contribute to the company's long-term vision, strategic planning, and global growth initiatives. He is also the Managing Director of Senores Pharmaceuticals Limited and is a convener of the pharma panel in the Confederation of Indian Industry (CII), Gujarat State Council.

Particulars of his qualification, brief resume, area of expertise and other details are provided in the Annexure -A attached to this Notice.

In accordance with the applicable provisions of the Companies Act, 2013, approval of members is being sought, by way of an ordinary resolution, for re-appointment of Mr. Swapnil Jatinbhai Shah (DIN: 05259821) as the Chairman and Non- Executive, Non- Independent Director of the Company.

Accordingly, the Board recommends the resolution set forth in Item No. 6 relating to re-appointment of Mr. Swapnil Jatinbhai Shah (DIN: 05259821) as the Chairman and Non- Executive,

Non- Independent Director of the Company, by way of Ordinary Resolution.

Except Mr. Swapnil Jatinbhai Shah and Mrs. Anar Swapnil Shah (spouse of Mr. Swapnil Jatinbhai Shah), no other director(s) and Key Managerial Personnel(s) or their relatives, is in any way, concerned or interested, financially or otherwise, in this resolution.

Item No. 7

Mrs. Anar Swapnil Shah (DIN: 06895297) was re-designated as a Whole Time Director of the Company by the members in the Extra-ordinary General Meeting held on January 21, 2023, for a term of 3 (three) years with effect from January 16, 2023 and had also approved her remuneration. Subsequently, upon her request, the Nomination and Remuneration Committee ("NRC") and the Board of Directors at their respective meetings held on May 17, 2025, re-designated her as the Non- Executive, Non- Independent Director of the Company with effect from May 18, 2025 for remaining period of her tenure. As per the terms of her appointment, the current tenure of Mrs. Anar Swapnil Shah, as the Non- Executive, Non- Independent Director is due for completion on January 15, 2026.

Hence, on the recommendations of Nomination & Remuneration Committee (NRC), the Board of Directors in its meeting held on August 29, 2025, have approved the re-appointment of Mrs. Anar Swapnil Shah as the Non- Executive, Non- Independent Director of the Company with effect from January 16, 2026, to hold office for a second term of 3 (three) consecutive years commencing from January 16, 2026 to January 15, 2029 (both days inclusive) liable to retire by rotation.

The Company has received a Notice in writing from a member of the Company under Section 160 of the Companies Act, 2013 proposing her candidature as Director on the Board of the Company.

With regard to the proposed appointment, the Company has received consent from Mrs. Anar Swapnil Shah to act as a Director, a declaration that she is not disqualified from being appointed as Director in terms of Section 164 of the Act and a declaration to the effect that she is not debarred or disqualified from being appointed or continuing as a director of any company by the SEBI or Ministry of Corporate Affairs or any such authority.

Mrs. Anar Shah, the Promoter and Non- Executive Director of the Company, is a silver medalist in Master of Business Administration with a specialization in Family Business & Entrepreneurship from Nirma University. She is a dentist by education and holds a bachelor's degree in Dental Surgery from BVDU Medical College. With a strong academic foundation, Mrs. Anar Shah brings valuable perspectives on human resource development and governance. While not involved in day-to-day operations, she contributes at the Board level by advising on workforce strategy and organizational culture, supporting the company's vision for a resilient and people-driven business.

Particulars of her qualification, brief resume, area of expertise and other details are provided in the Annexure – A attached to this Notice.

In accordance with the applicable provisions of the Companies Act, 2013, approval of members is being sought, by way of an ordinary resolution, for re-appointment of Mrs. Anar Swapnil Shah (DIN: 06895297) as the Non- Executive, Non- Independent Director of the Company.

Accordingly, the Board recommends the resolution set forth in Item No. 7 relating to re-appointment of Mrs. Anar Swapnil

Shah (DIN: 06895297) as the Non- Executive, Non- Independent Director of the Company, by way of Ordinary Resolution.

Except Mrs. Anar Swapnil Shah and Mr. Swapnil Jatinbhai Shah (spouse of Mrs. Anar Swapnil Shah), no other director(s) and Key Managerial Personnel(s) or their relatives, is in any way, concerned or interested, financially or otherwise, in this resolution.

By order of the Board of Directors
For **Remus Pharmaceuticals Limited**

Sd/-
Deval Patel
Company Secretary and Compliance Officer

Place: Ahmedabad

Date: 29/08/2025

Registered Office:

1101 to 1103, South Tower,
One 42, B/H Ashok Vatika,
Nr. Jayantilal Park BRTS,
Ambli Bopal Road,
Ahmedabad – 380 054, Gujarat
CIN: L24232GJ2015PLC084536

Annexure -A**DETAILS OF THE DIRECTORS SEEKING APPOINTMENT / RE-APPOINTMENT/REVISION IN REMUNERATION**

(Pursuant to regulation 36 (3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings (SS-2))

Name of the Director	Arpit Deepakkumar Shah	Roma Vinodbhai Shah	Swapnil Jatinbhai Shah	Anar Swapnil Shah
Designation	Managing Director	Whole -Time Director	Chairman and Non- Executive, Non- Independent Director	Non- Executive, Non- Independent Director
DIN	07214641	07214632	05259821	06895297
Age	37 years	37 years	40 years	37 years
Date of Birth	September 11, 1987	December 17, 1987	July 01, 1985	January 17, 1988
Qualifications	Bachelor of Engineering (Information Technology) from Saurashtra University	1. Bachelor of Pharmacy from Gujarat University 2. Master of Science (Pharmaceutical Manufacturing) from Stevens Institute of Technology, New Jersey	1. Bachelor of Engineering (Chemical) from Gujarat University 2. Master of Business Administration from Hofstra University	1. Bachelor of Dental Surgery from Bharati Vidyapeeth Deemed University 2. Master of Business Administration from Nirma University
Experience/ Expertise	Mr. Arpit Deepakkumar Shah is the Promoter and serves as the Managing Director of the Company. An engineer by qualification, he brings over 15 years of experience in business development and strategic planning. He plays a pivotal role in driving the Company's growth and expansion, leading business development and marketing initiatives with a strong focus on identifying new geographies, building international partnerships, and expanding the company's footprint across semi-regulated and emerging markets. His leadership has been instrumental in strengthening Remus's global presence and fostering sustainable growth.	Ms. Roma Vinodbhai Shah, the Promoter and Whole Time Director of the Company holds a master's degree in Pharmaceutical Manufacturing from the USA and a bachelor's degree in Pharmacy from India. Having more than a decade of experience she brings deep technical expertise and global perspective to the organization. She has been a strong pillar in driving the Company's success across Regulatory Affairs, R&D, and strategic business management. Her specialization in critical technical areas ensures the Company's adherence to international quality standards and regulatory compliance, with deep industry insights, ensuring regulatory excellence and global market readiness.	Mr. Swapnil Shah holds a master's degree in Business Administration with a specialization in Finance & International Business from Hofstra University, New York, and a bachelor's degree in Chemical Engineering from Nirma University. Mr. Swapnil Shah is the Promoter and Chairman and Non- Executive Director and a key strategic advisor to the Company. With over 18 years of experience in the pharmaceutical sector, he brings valuable insights in business development, corporate strategy, and global operations. While not involved in day-to-day operations, he continues to contribute to the company's long-term vision, strategic planning, and global growth initiatives. He is also the Managing Director of Senores Pharmaceuticals Limited and is a convenor of the pharma panel in the Confederation of Indian Industry (CII), Gujarat State Council.	Mrs. Anar Shah, the Promoter and Non- Executive Director of the Company, is a silver medalist in Master of Business Administration with a specialization in Family Business & Entrepreneurship from Nirma University. She is a dentist by education and holds a bachelor's degree in Dental Surgery from BVDU Medical College. With a strong academic foundation and more than a decade of experience, Mrs. Anar Shah brings valuable perspectives on human resource development and governance. While not involved in day-to-day operations, she contributes at the Board level by advising on workforce strategy and organizational culture, supporting the company's vision for a resilient and people-driven business.

Name of the Director	Arpit Deepakkumar Shah	Roma Vinodbhai Shah	Swapnil Jatinbhai Shah	Anar Swapnil Shah
Terms and conditions of appointment or re-appointment	Re-appointment as Managing Director	Re-appointment as a Whole Time Director	Re -appointment as the Chairman and Non-Executive, Non-Independent Director	Re-appointment as a Non-Executive, Non-Independent Director
Details of remuneration sought to be paid (₹. In Crores) per annum	As set out in the Item No. 4 of the Explanatory Statement to the Notice.	As set out in the Item No. 5 of the Explanatory Statement to the Notice.	Due to change in designation, no remuneration is proposed to be paid to the Non- Executive Director	Due to change in designation, no remuneration is proposed to be paid to the Non- Executive Director
Details of remuneration last drawn (₹ In Crores)	₹ 2.07	₹ 1.10	₹1.35	₹ 0.80
Date of first appointment on the Board	September 21, 2015	September 21, 2015	September 21, 2015	December 30, 2020
Shareholding in the Company as on March 31, 2025	10,38,500	10,12,400	10,00,000	10,00,000
Inter-se relationship with other Directors, Manager and other Key Managerial Personnel of the Company	He is spouse of Ms. Roma Vinodbhai Shah.	She is spouse of Mr. Arpit Deepakkumar Shah.	He is spouse of Mrs. Anar Swapnil Shah.	She is spouse of Mr. Swapnil Jatinbhai Shah.
Number of Meetings of the Board attended during the financial year	6/6	6/6	6/6	5/6
Membership/ Chairmanship in Committees in other companies as on March 31, 2025.	Member of Audit Committee: <ul style="list-style-type: none"> - Remus Pharmaceuticals Limited Member of Stakeholders Relationship Committee: <ul style="list-style-type: none"> - Remus Pharmaceuticals Limited 	NIL	Member of Audit Committee: <ul style="list-style-type: none"> - Remus Pharmaceuticals Limited - Senores Pharmaceuticals Limited Member of Stakeholders Relationship Committee: <ul style="list-style-type: none"> - Remus Pharmaceuticals Limited - Senores Pharmaceuticals Limited Member of Nomination and Remuneration Committee: <ul style="list-style-type: none"> - Ratnatris Pharmaceuticals Private Limited 	NIL

Name of the Director	Arpit Deepakkumar Shah	Roma Vinodbhai Shah	Swapnil Jatinbhai Shah	Anar Swapnil Shah
List of Directorship held in other companies as on March 31, 2025	<ul style="list-style-type: none"> Relius Lifesciences Private Limited Ratnatris Pharmaceuticals Private Limited Senores Pharmaceuticals Limited 	<ul style="list-style-type: none"> Relius Lifesciences Private Limited 	<ul style="list-style-type: none"> Senores Pharmaceuticals Limited Renosen Pharmaceuticals Private Limited Ratnatris Pharmaceuticals Private Limited Relius Lifescience Private Limited Havix Group, Inc. d/b/a Aavis Pharmaceuticals Senores Pharmaceuticals Inc. Renosen Ventures Inc. 	<ul style="list-style-type: none"> Relius Lifesciences Private Limited Renosen Pharmaceuticals Private Limited Renosen Ventures INC.
Listed entities from which the person has resigned from Directorships in the past three years	None	None	None	None
Listed entities from which the person has resigned from Chairmanship/ Membership in the past three years	None	None	None	None

Annexure -B

DISCLOSURE PURSUANT TO SECTION II OF PART II OF SCHEDULE V OF THE COMPANIES ACT, 2013 IN RESPECT OF THE RESOLUTIONS SET OUT AT ITEM NUMBER 4 AND 5 OF THE NOTICE OF THIS AGM

I. GENERAL INFORMATION:

- (i) **Nature of Industry:** Our Company is engaged in pharmaceutical business marketing in international market. We are also engaged in distribution of pharmaceutical products through third party distribution network. We offer wide range of pharmaceutical formulations and products manufactured on contract manufacturing and on loan license basis.
- (ii) **Date of commencement of commercial production:** Not Applicable
- (iii) **In case of new companies, expected date of commencement of activities:** Not Applicable
- (iv) **Financial performance:** Based on the Audited financial results for the last 3 years:

(₹ in Crores)

Particulars	2024-2025	2023-2024*	2022-2023
Total Revenue	79.16	63.94	45.57
Profit before Depreciation, Financial Expenses & Tax	28.89	23.82	14.22
Depreciation, Financial Expenses & Tax	8.99	7.20	3.68
Net Profit after Tax	19.90	16.62	10.54
Paid up Share Capital	5.89	1.47	1.09
Reserves & Surplus	236.33	152.08	17.99

*The Company voluntarily adopted IND- AS for the first time w.e.f. April 01, 2024, hence the financials for FY 2023-24 have been restated.

- (v) **Foreign investments or collaborators, if any:**

For details of investment made by the Company, please refer the note no.06 of the Standalone Financial Statements forming part of the Annual Report for FY 2024-25 being sent along with this Notice. The Company has not entered into any material foreign collaborations.

As on March 31, 2025, the Shareholding of Foreign Institutional Investors, Foreign Nationals and Foreign Companies, in the Company is detailed as under:

Particulars	No. of Shares	Percentage (%)
Non-Resident Indians	9,125	0.15
Non-Resident (Non Repatriable)	1,775	0.03
FPI (Corporate) - I	2,81,100	4.77

II. INFORMATION ABOUT THE DIRECTORS:

- (i) **Background details:**

Name of Director	Mr. Arpit Deepakkumar Shah	Ms. Roma Vinodbhai Shah
Designation	Managing Director	Whole Time Director
Education	Bachelor of Engineering (Information Technology) from Saurashtra University	1. Bachelor of Pharmacy from Gujarat University 2. Master of Science (Pharmaceutical Manufacturing) from Stevens Institute of Technology, New Jersey
Past Experience	Mr. Arpit Shah is Director and promoter of the company having more than half a decade of experience in the USA and almost a decade in India.	Mrs. Roma Shah is Director and promoter of the company with nearly a decade of experience in the Pharmaceutical Industry.

- (ii) **Past remuneration during the last three financial years:**

Financial Years	Remuneration of Mr. Arpit Deepakkumar Shah (₹ in Crores)	Remuneration of Ms. Roma Vinodbhai Shah (₹ in Crores)
2024-25	2.07	1.10
2023-24	1.68	0.90
2022-23	1.53	0.94

(iii) Recognition or Awards: Not Applicable**(iv) Job Profile and their suitability:**

Mr. Arpit Shah, Promoter and Managing Director has been taking care of day-to-day activities like Generating new business and building a market with his marketing skills and has played a key role in company's growth. He has also played an aggressive role in strategizing and putting in place a global marketing plan. He firmly believes that businesses are responsible for employing ethical, fair, and ecologically sensitive business practices.

Ms. Roma Shah, Promoter and Whole Time Director is robust in managing Regulatory Affairs, FR&D, generating new business, and managing existing clients. She is building strong grounds in Validation Engineering, Regulatory Affairs, and CMC.

(v) Remuneration proposed:

Proposed remuneration is as mentioned in the explanatory statement in Item no. 4 and 5.

(vi) Comparative remuneration profile with respect to industry, size of the Company, profile of the position and person (in case of expatriates the relevant details would be with respect to the country of his origin):

Taking into consideration the size of the Company, the profile of the Managing Director and Executive Directors and the responsibilities shouldered by them and the industry benchmarks, the remuneration proposed to be paid is commensurate with the remuneration paid to similar senior level counterparts in other Companies in the industry.

It is further informed that all the Directors are resident Indians, and hence no expatriate remuneration comparison is applicable.

(vii) Pecuniary relationship(s) directly or indirectly with the Company, Co-relationship with the managerial personnel, if any:

Besides payment of remuneration, Mr. Arpit Shah and Ms. Roma Shah do not have any pecuniary relationship with the Company other than what has been

mentioned under related party transactions in annual report of FY 2024-2025. Further, they are promoters of the Company and are also holding equity shares of the Company as already disclosed in the report.

III. OTHER INFORMATION:**(i) Reasons of loss or inadequate profits:**

The Company has consistently demonstrated improving performance year over year. However, external headwinds such as global market uncertainties, elevated inflation levels, currency fluctuations, and other macroeconomic factors have posed challenges. Consequently, these conditions have impacted the Company's profitability, resulting in profits that do not fully reflect the underlying operational progress.

(ii) Steps taken or proposed to be taken for improvement and expected increase in productivity and profits in measurable terms:

The Company is implementing strategic measures to improve profitability and drive sustainable growth. Operational efficiency is being strengthened through supply chain optimization and cost control initiatives. These combined efforts are designed to enhance margins and improve the Company's financial performance, subject to external market conditions.

(iii) Expected increase in productivity and profits in measurable terms:

The implementation of these initiatives is expected to enhance overall profitability, contributing to steady margin improvement and stronger financial performance in the coming periods. Continued focus on operational efficiency and strategic expansion will further support sustainable growth. These efforts reflect the Company's commitment to long-term value creation for all stakeholders.

(iv) Disclosures:

The information and disclosures of the remuneration package of the managerial personnel have been mentioned in the resolutions and explanatory statement as stated above.

By order of the Board of Directors
For **Remus Pharmaceuticals Limited**

Sd/-
Deval Patel

Company Secretary and Compliance Officer

Place: Ahmedabad
Date: 29/08/2025

Registered Office:

1101 to 1103, South Tower,
One 42, B/H Ashok Vatika,
Nr. Jayantilal Park BRTS,
Ambli Bopal Road,
Ahmedabad – 380 054, Gujarat
CIN: L24232GJ2015PLC084536